Intellia Therapeutics NTLA announced that the FDA has accepted the biologics license application (BLA) seeking approval for lonvoguran ziclumeran (lonvo-z; formerly NTLA-2002), an in vivo CRISPR-based gene-editing therapy, for the treatment of hereditary angioedema (HAE).
With the FDA granting a priority review to the BLA, a decision from the regulatory body is expected on March 10, 2027.
If approved, lonvo-z will become the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE.
The regulatory body has informed Intellia that it does not currently plan to hold an advisory committee meeting to discuss the BLA for lonvo-z.
In April 2026, Intellia initiated a rolling submission of a BLA to the FDA seeking approval for lonvo-z for the treatment of HAE.
NTLA’s Price Performance
Year to date, shares of Intellia have rallied 41.7% compared with the industry’s increase of 11.2%.
Image Source: Zacks Investment Research
NTLA’s Recent Progress With Lonvo-z
The BLA for lonvo-z was based on positive data from the global phase III HAELO study.
The phase III HAELO study met its primary endpoint and all key secondary endpoints, with a one-time infusion of lonvo-z reducing attacks by 87% compared with placebo over the six-month efficacy evaluation period.
In June 2026, the company reported additional positive data from the HAELO study, further highlighting lonvo-z's potential to deliver meaningful disease control for HAE patients.
HAE is a rare genetic disorder marked by recurrent, potentially life-threatening swelling caused by excess bradykinin.
The company plans to commercially launch lonvo-z in the first half of 2027, upon potential approval in the United States.
NTLA’s Other Pipeline Progress
Besides lonvo-z, Intellia’s other lead candidate, nexiguran ziclumeran (nex-z; formerly NTLA-2001), a CRISPR-based gene-edited therapy, is being developed in collaboration with Regeneron Pharmaceuticals REGN.
While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits.
Nex-z is being evaluated in two late-stage studies, MAGNITUDE and MAGNITUDE-2, for treating ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTR amyloidosis with polyneuropathy (ATTRv-PN), respectively. If the data from the studies are found to be positive, it should likely enable global regulatory filings for nex-z.
NTLA’s Zacks Rank & Stocks to Consider
Intellia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Repligen RGEN and Anika Therapeutics ANIK, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61 during the same time. RGEN’s shares have gained 2.9% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Anika Therapeutics’ 2026 bottom line have moved from a loss of 12 cents per share to earnings of $1.05 per share. Earnings estimates for 2027 have increased from 16 cents to 95 cents during the same time. ANIK’s shares have surged 119% year to date.
Anika Therapeutics’ earnings beat estimates in each of the trailing three quarters, with the average surprise being 950.00%.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intellia Therapeutics, Inc. (NTLA): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Repligen Corporation (RGEN): Free Stock Analysis Report
Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).